ABCL
Price
$4.22
Change
+$0.06 (+1.44%)
Updated
Sep 5 closing price
Capitalization
1.26B
64 days until earnings call
DNA
Price
$11.15
Change
-$0.53 (-4.54%)
Updated
Sep 5 closing price
Capitalization
660.08M
Interact to see
Advertisement

ABCL vs DNA

Header iconABCL vs DNA Comparison
Open Charts ABCL vs DNABanner chart's image
AbCellera Biologics
Price$4.22
Change+$0.06 (+1.44%)
Volume$4.17M
Capitalization1.26B
Ginkgo Bioworks Holdings
Price$11.15
Change-$0.53 (-4.54%)
Volume$2.09M
Capitalization660.08M
ABCL vs DNA Comparison Chart in %
Loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABCL vs. DNA commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and DNA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (ABCL: $4.22 vs. DNA: $11.15)
Brand notoriety: ABCL and DNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 74% vs. DNA: 126%
Market capitalization -- ABCL: $1.26B vs. DNA: $660.08M
ABCL [@Biotechnology] is valued at $1.26B. DNA’s [@Biotechnology] market capitalization is $660.08M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileDNA’s FA Score has 1 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • DNA’s FA Score: 1 green, 4 red.
According to our system of comparison, both ABCL and DNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 2 TA indicator(s) are bullish while DNA’s TA Score has 2 bullish TA indicator(s).

  • ABCL’s TA Score: 2 bullish, 4 bearish.
  • DNA’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, ABCL is a better buy in the short-term than DNA.

Price Growth

ABCL (@Biotechnology) experienced а +0.96% price change this week, while DNA (@Biotechnology) price change was -12.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

ABCL is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($1.26B) has a higher market cap than DNA($660M). ABCL YTD gains are higher at: 44.027 vs. DNA (13.544). ABCL has higher annual earnings (EBITDA): -197.92M vs. DNA (-292.97M). ABCL has more cash in the bank: 553M vs. DNA (474M). ABCL has less debt than DNA: ABCL (142M) vs DNA (429M). DNA has higher revenues than ABCL: DNA (231M) vs ABCL (32.9M).
ABCLDNAABCL / DNA
Capitalization1.26B660M191%
EBITDA-197.92M-292.97M68%
Gain YTD44.02713.544325%
P/E RatioN/AN/A-
Revenue32.9M231M14%
Total Cash553M474M117%
Total Debt142M429M33%
TECHNICAL ANALYSIS
Technical Analysis
ABCLDNA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
88%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 5 days ago
85%
Bearish Trend 11 days ago
86%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SDMGX20.900.34
+1.65%
Sit Developing Markets Growth
QTENX12.300.12
+0.99%
AQR Emerging Multi-Style II N
IUEFX29.130.12
+0.41%
JPMorgan International Focus R5
PRJCX41.050.05
+0.12%
PGIM Jennison Global Opportunities C
HMCNX15.400.01
+0.06%
Harbor Mid Cap Investor

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with RXRX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+1.44%
RXRX - ABCL
57%
Loosely correlated
+1.99%
CRSP - ABCL
56%
Loosely correlated
+4.02%
VCYT - ABCL
56%
Loosely correlated
+2.89%
ABSI - ABCL
53%
Loosely correlated
+2.50%
BEAM - ABCL
51%
Loosely correlated
+12.62%
More

DNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNA has been loosely correlated with VCYT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNA
1D Price
Change %
DNA100%
-4.54%
VCYT - DNA
58%
Loosely correlated
+2.89%
RXRX - DNA
52%
Loosely correlated
+1.99%
ABCL - DNA
49%
Loosely correlated
+1.44%
CRSP - DNA
48%
Loosely correlated
+4.02%
ABSI - DNA
48%
Loosely correlated
+2.50%
More